Regular Article
5-Azacytidine Modulates the Response of Sensitive and Multidrug-Resistant K562 Leukemic Cells to Cytostatic Drugs

https://doi.org/10.1006/bcmd.2001.0427Get rights and content

Abstract

ABSTRACT

In an endeavor to improve responsiveness of tumor cells to drug combination treatments, we analyzed the effect of 5-azacytidine (5AC) as a model compound for a new class of drugs, DNA-demethylating agents. We used parental K562/WT chronic myelogenous leukemia cells and a multidrug-resistant subline thereof, K562/ADM. Multidrug-resistant cells were more resistant to daunorubicin, but more sensitive to cisplatin than parental K562 cells as measured by growth inhibition and apoptosis assays. Resistance to daunorubicin can be explained by amplification of the MDR1 drug transporter gene. Cisplatin induced more DNA damage in specific genes and in the entire genome of K562/ADM cells compared to K562/WT cells using PCR stop assays and atomic absorption spectroscopy. Pretreatment with 5AC modulated the response of K562/ADM cells toward MDR-type drugs (daunorubicin, vincristine, etoposide) and reduced function and expression of MDR1 as analyzed by flow cytometry and RT-PCR. Analysis of CpG island methylation in the promotor region of the MDR1 gene by bisulfite sequencing and a methylation-sensitive HpaII-digestion/PCR approach revealed that methylation of the MDR1 promotor of K562/ADM cells was greater than in K562/WT cells. 5AC treatment completely abolished MDR1 promotor methylation. The unexpected observation that DNA demethylation by 5AC rather decreases than increases MDR1 expression in K5612/ADM cells points to still unexplored sequences in the MDR1 promotor whose transcriptional activity may be affected by the methylation status. 5AC pretreatment also modulated K562/WT and K562/ADM cells to non-MDR-type drugs such as cisplatin and increased cisplatin-induced DNA damage.

References (44)

  • J.M. Rowe

    Treatment of acute myelogenous leukemia in older adults

    Leukemia

    (2000)
  • S. Akiyama et al.

    Resistance to cisplatin

    Anticancer Drug Res.

    (1999)
  • P.A. Jones et al.

    Hemimethylated duplex DNAs prepared from 5-azacytidine-treated cells

    Nucleic Acids Res.

    (1982)
  • W.H. Lee et al.

    Cytidine methylation of regulatory sequences near the p-class glutathione S-transferase gene accompanies human prostatic carcinogenesis

    Proc. Natl. Acad. Sci. USA

    (1994)
  • M. Szyf

    The DNA methylation machinery as a target for anticancer therapy

    Pharmacol. Ther.

    (1996)
  • T. Efferth et al.

    Expression of apoptosis-related oncoproteins and modulation of apoptosis by caffeine in human leukemic cells

    J. Cancer Res. Clin. Oncol.

    (1995)
  • W.G. Telford et al.

    Comparative evaluation of several DNA binding dyes in the detection of apoptosis associated with chromatin degradation by flow cytometry

    Cytometry

    (1992)
  • T. Efferth et al.

    Apoptosis and resistance to daunorubicin in human leukemic cells

    Leukemia

    (1997)
  • K.E. Noonan et al.

    mRNA phenotyping by enzymatic amplification of randomly primed cDNA

    Nucleic Acids Res.

    (1988)
  • T. Efferth et al.

    Damage of the kinesin heavy chain gene contributes to the antagonism of cisplatin and paclitaxel

    Anticancer Res.

    (2000)
  • G.S. Watts et al.

    Methylation of discrete regions of the O6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene

    Mol. Cell. Biol.

    (1997)
  • Cited by (0)

    Communicated by M. Lichtman, M.D., 05/10/01

    f1

    Correspondence and reprint requests to: Thomas Efferth, Virtual Campus Rhineland-Palatinate, P.O. Box 4380, 55033 Mainz, Germany. E-mail: [email protected].

    View full text